{"id":"csf2ra","name":"GM-CSF receptor (CSF2RA)","symbol":"CSF2RA","route":"/targets/csf2ra/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2435","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198223","uniprot":"https://www.uniprot.org/uniprotkb/P15509/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P15509","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2364169","open-targets":"https://platform.opentargets.org/target/ENSG00000198223","civic":"https://civicdb.org/genes/1438/summary","oncokb":"https://www.oncokb.org/gene/CSF2RA","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CSF2RA","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CSF2RA","depmap":"https://depmap.org/portal/gene/CSF2RA?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000198223-CSF2RA","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1438","omim":"https://www.omim.org/entry/306250"}],"products":[{"id":"sargramostim","name":"Sargramostim","status":"established","modality":"Recombinant granulocyte-macrophage colony-stimulating factor, injection","route":"/drugs/sargramostim/"}],"trials":[{"id":"nct00769704","name":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","nct":"NCT00769704","phase":"3","status":"completed"},{"id":"anbl17p1","name":"ANBL17P1","nct":"NCT03786783","phase":"2","status":"positive"},{"id":"anbl1221","name":"ANBL1221","nct":"NCT01767194","phase":"2","status":"positive"},{"id":"nct00450619","name":"153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer","nct":"NCT00450619","phase":"2","status":"completed"},{"id":"nct07078604","name":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","nct":"NCT07078604","phase":"2","status":"recruiting"},{"id":"nct05269381","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","nct":"NCT05269381","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["partner-therapeutics"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}